# Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

> **NCT00541086** · PHASE3 · UNKNOWN · sponsor: **Gruppo Italiano Mammella (GIM)** · enrollment: 3697 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** anastrozole
- **DRUG:** exemestane
- **DRUG:** letrozole
- **DRUG:** tamoxifen citrate

## Key facts

- **NCT ID:** NCT00541086
- **Lead sponsor:** Gruppo Italiano Mammella (GIM)
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-03
- **Primary completion:** 2020-07
- **Final completion:** 2020-07
- **Target enrollment:** 3697 (ACTUAL)
- **Last updated:** 2020-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00541086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00541086, "Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00541086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*